Marilyne AndersenMarilyne Andersen est professeure ordinaire en technologies durables de la construction et dirige le Laboratoire Performance Intégrée au Design (LIPID) qu'elle a fondé en automne 2010. Elle a été Doyenne de la Faculté de l'Environnement Naturel, Architectural et Construit (ENAC) de l'EPFL de 2013 à 2018 et est la Directrice Académique du Smart Living Lab à Fribourg. Elle co-dirige également le Student Kreativity and Innovation Laboratory (SKIL) à l'ENAC.Avant de rejoindre l'EPFL, elle était professeure assistante puis associée (tenure-track) dans le Building Technology Group du MIT, au sein du Département d'Architecture, où elle a fondé et dirigé le MIT Daylighting Lab depuis 2004. Elle a aussi été professeure invitée à la Singapore University of Technology and Design en 2019. Marilyne Andersen détient un Master ès sciences en physique et s'est spécialisée dans l'éclairage naturel durant sa thèse dans la physique du bâtiment à l'EPFL au Laboratoire d'énergie solaire et de physique du bâtiment (LESO) ainsi qu'en tant que chercheuse invitée au Building Technologies Department du Lawrence Berkeley National Laboratory en Californie. Ses recherches se situent à l'interface entre sciences, ingénierie et architecture avec une attention spécifique sur l'impact de la lumière naturelle sur les occupants d'un bâtiment. Avec un focus sur les questions de confort, de perception et de santé et leurs implications énergétiques, ces efforts de recherche visent à une intégration plus profonde de la performance lumineuse et du confort intérieur dans le processus de conception, grâce à de nouvelles synergies avec d'autres domaines scientifiques, comme la chronobiologie et les neurosciences ainsi que la psychophysique ou l'informatique et l'imagerie digitale. Elle s'appuie sur ces recherches pour les étendre à la pratique architecturale à travers la startup OCULIGHT dynamics qu'elle a co-fondée, et qui offre des services spécialisés en éclairage naturel avec un accent particulier sur les effets psycho-physiologiques de la lumière naturelle sur les occupants d'un bâtiment. Elle est l'auteure de plus de 200 articles référés publiés dans des revues scientifiques et lors de conférences internationales, ainsi que la lauréate de plusieurs bourses et prix dont: le Daylight Award for Research (2016), onze prix et distinctions pour ses publications (2009, 2011, 2012, 2015, 2018, 2019, 2021) dont le Taylor Technical Talent Award 2009 décerné par la Illuminating Engineering Society, le 3M Non-Tenured Faculty Award (2009), le Mitsui Career Development Professorship au MIT (2008) et le prix EPFL de la Fondation Chorafas en durabilité attribué pour sa thèse (2005). Ses travaux de recherche ou d'enseignement ont été soutenus par des organisations professionnelles, institutionnelles et industrielles tels que les Fonds National pour la Recherche Scientifique (en Suisse et aux USA), la fondation Velux, le programme Européen Horizon 2020, la Boston Society of Architects, la MIT Energy Initiative et InnoSuisse. Elle a été la directrice et responsable académique de l'équipe suisse et son projet NeighborHub, qui a gagné la compétition U.S. Solar Decathlon 2017 avec 8 podiums sur 10 épreuves. Elle est membre du Conseil de la Fondation LafargeHolcim pour la construction durable et dirige son Comité Académique. Elle est également membre du conseil éditorial de la revue scientifique Building and Environment chez Elsevier ainsi que des revues LEUKOS (de la Illuminating Engineering Society) et Buildings and Cities chez Taylor et Francis. Elle est Experte pour le Conseil d'Innovation InnoSuisse ainsi que membre fondatrice et membre du Conseil de la Fondation Culture du Bâti (CUB). Elle est aussi membre fondatrice de la Daylight Academy et membre active de plusieurs comités de l'Illuminating Engineering Society (IES) et de la Commission Internationale de l'Eclairage (CIE).
Pierre DillenbourgAncien instituteur primaire, Pierre Dillenbourg obtient un master en Sciences de lEducation (Université de Mons, Belgique). Dans son projet de master en 1986, il est l'un des premiers au monde à appliquer les méthodes de 'machine learning' à l'éducation, afin de développer un 'self-improving teaching system'. Ceci lui permettra de débuter une thèse de doctorat en informatique à l'Université de Lancaster (UK) dans le domaine des applications éducatives de lintelligence artificielle. Il a été Maître dEnseignement et de Recherche à lUniversité de Genève. Il rejoint l'EPFL en 2012, où Il fut le directeur du Centre de Recherche sur l'Apprentissage, la formation et ses technologies(CRAFT), puis académique du Centre pour l'Education à l'Ere Digitale (CEDE) qui met en oeuvre la stratégie MOOC de l'EPFL (plus de 2 millions d'inscriptions). Il est actuellement professeur ordinaire en technologies de formation aux sein de la faculté Informatique et Communications et dirige laboratoire d'ergonomie éducative (CHILI). Depuis 2006, il a aussi été le directeur de DUAL-T, la 'leading house' dédiée aux technologies pour les systèmes de formation professionnelle duale. Il a fondé plusieurs start-ups dans l'éducation et rejoint plusieurs conseils d'administration. En 2017, Il a créé avec des collègues le 'Swiss EdTech Collider', un incubateur qui rassemble 80 start-ups dans le domaine des technologies éducatives. En 2018, ils ont lancé LEARN, le centre EPFL pour les sciences de l'apprentissage, lequel regroupe les initiatives locales en innovation éducative. Pierre est un 'inaugural fellow of the International Society of Learning Sciences'. Il est actuellement le Vice-Président Associé pour l'Education à l'EPFL.
Hilal Lashuel2012-2013 Visiting Professor, Standford University. Stanford School of Medicine
2011- Associate Professor of Life Sciences-Brain Mind Institute-EPFL
Dir. Laboratory of Chemical Biology of Neurodegeneration
2005-2011 Assistant Professor of Life Sciences-Brain Mind Institute-EPFL
Dir. Laboratory of Molecular Neurobiology and Neuroproteomics
2005-2008 Director- EPFL Proteomic Core Facility
2002-2004 Instructor of Neurology- Harvard Medical School and Brigham and Women's
Hospital
2001-2002 Sabbatical Fellow- Laboratory for Drug Discovery in Neurodegeneration
Harvard Medical School,
2001-2002 Post-doctoral Fellow- Center for Neurologic Diseases
Harvard Medical School and Brigham and Women's Hospital
Advisor- Prof. Peter T. Lansbury
2000-2001 Research Scientist, The Picower Institute for Medical Research, Great Neck
New York
1994-2000 PhD Student; Texas A&M University and the Scripps Research Institute
Advisor- Prof. Jeffery W. Kelly
1990-1994 B.S. City University of New York, Brooklyn College
Dr. Hilal A. Lashuel received his B.Sc. degree in chemistry from the City University of New York in 1994 and completed his doctoral studies at Texas A&M University and the Scripps Research Institute in 2000. After obtaining his doctoral degree, he became a research fellow at the Picower Institute for Medical Research in Long Island New York. In 2001, he moved to Harvard Medical School and the Brigham and Women's Hospital as a research fellow in the Center for Neurologic Diseases and was later promoted to an instructor in neurology at Harvard Medical School. During his tenure (2001-2004) at Harvard Medical School his work focused on understanding the mechanisms of protein misfolding and fibrillogenesis and the role of these processes in the pathogenesis of Parkinson's and Alzheimer's disease. In 2005 Dr. Lashuel moved Switzerland to join the Brain Mind Institute at the Swiss Federal Institute of Technology Lausanne as a tenure-track assistant professor in neurosciences. Currently, Dr. Lashuel is an associate professor of life sciences and the director of the laboratory of molecular and chemical biology of neurodegeneration. (http://lashuel-lab.epfl.ch/).
Research efforts in the Lashuels laboratory focus on understanding the molecular mechanisms of neurodegeneration and developing novel strategies to diagnose and treat neurodegenerative diseases such as Alzheimers and Parkinsons disease. Research in the Lashuel lab is funded by several international funding agencies and foundations, including the Swiss National Science Foundation, European FP7 program (Marie Curie and ERC grants), Human Science Frontiers, Strauss Foundation, Cure the Huntingtons disease foundation and Michael J Fox foundation and is supported by collaborations with pharmaceutical and biotech companies (http://lashuel-lab.epfl.ch/page-50538-en.html), Nestle, Merck-Serono, AC Immune and Johnson and Johnson.
Dr. Lashuels research has resulted in the characterization of novel quaternary structure intermediates on the amyloid pathway, identification of potential therapeutic targets, and new hypotheses concerning the mechanisms of pathogenesis in Alzheimers disease, Parkinsons disease and related disorders. Dr. Lashuel scientific contribution to this field includes i) more than100 publications in major peer reviewed journals including Nature journals, Cell, PNAS, JBC, J. Neuroscience JACS, and Angewandtie Chemie; ii) three patents on novel strategies for preventing protein aggregation and treating autoimmune and inflammatory diseases; iii) more than 150 invited lectures since 2002 and more than 5500 citations (7800 citation-Google Scholar) since 1996. Dr. Lashuel has received several pre-doctoral and post-doctoral awards and fellowships and was the recipient of two prestigious awards given to young investigators; Human Science Frontiers young investigator research award and the European Research Council (ERC) starting independent researcher grant and the ERC proof of concept award (2013) These awards provide more than $2.5 Million to Dr. Lashuel to translate some of his ideas and projects into novel strategies for diagnosing and treating neurodegenerative diseases such as Alzheimers and Parkinsons disease. Dr. Lashuel has chaired and co-organized several international conferences and serves as an academic editor for PLoS ONE, an associate editor for frontiers of molecular neuroscience, member of the Editorial advisory board of ChemBioChem and ad hoc reviewer for several international scientific journals and funding agencies. Johan AuwerxJohan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
Freddy RadtkeFreddy Radtke obtained his Ph.D. in Molecular Biology from the University of Zürich in 1994. In 1995, he started his postdoctoral research in the laboratory of Michel Aguet at Genentech, Inc. (San Francisco, USA). In 1997, he returned to Switzerland with Michel Aguet and finished his postdoctoral fellowship at the Swiss Institute for Experimental Cancer Research (ISREC) in Lausanne. From 1999‑2005, he was a group leader and Associate Member at the Ludwig Institute for Cancer Research. Freddy Radtke then joined ISREC in January 2006 as a senior scientist and in July 2006, he was appointed Associate Professor at the EPFL School of Life Sciences
